Lv11
30 积分 2023-02-18 加入
Olverembatinib After Failure of Tyrosine Kinase Inhibitors, Including Ponatinib or Asciminib
2小时前
待确认
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML
1个月前
已完结
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML
1个月前
已关闭
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML
1个月前
已关闭
Molecular, clinical and therapeutic determinants of outcome in NPM1 mutated AML
1个月前
已关闭
Clinical implications of residual normal plasma cells within bone marrow across various disease stages in multiple myeloma
3个月前
已完结
Natural history, predictors of development of extramedullary disease, and treatment outcomes for patients with extramedullary multiple myeloma
7个月前
已完结
皖公网安备34019202002308
